The U.S. Food and Drug Administration (FDA) has approved Moderna’s mRESVIA, an mRNA vaccine that will protect adults aged 60 and older from respiratory syncytial virus (RSV), a lower respiratory tract disease that kills 6,000 to 10,000 people aged 65 and above each year.
This approval marks the first time an mRNA vaccine has been authorized for a condition other than COVID-19.
